Results - Details
Search command : Author="Ζώρας"
And Author="Οδυσσέας"
Current Record: 13 of 35
|
Identifier |
000409440 |
Title |
Διερεύνηση της συσχέτισης των ινσουλινόμορφων αυξητικών παραγόντων και των ενδοθηλινών με την παρουσία μικρομεταστατικών κυττάρων στο αίμα και την πρόγνωση γυναικών με πρώιμο καρκίνο του μαστού |
Alternative Title |
Investigation of the association between insulin growth factors and endothelins with the presence of circulating tumor cells and the prognosis in women with early breat cancer |
Author
|
Παπαδάκης, Γεώργιος Ζ.
|
Thesis advisor
|
Ζώρας, Οδυσσέας
Μαυρουδής, Δημήτριος
Γεωργούλιας, Βασίλειος
|
Reviewer
|
Καραντάνας, Απόστολος
Μακρυγιαννάκης, Αντώνιος
Σαμώνης, Γεώργιος
Περυσινάκης, Κων/νος
|
Abstract |
OBJECTIVE: Insulin-like growth factor (IGF)-axis is involved in human oncogenesis and metastasis development for various solid tumors including breast cancer. Aim of this study was to assess the association between IGF-1, IGF-binding protein-3 (IGFBP-3) serum levels and the presence of circulating tumor cells (CTCs) in the peripheral blood of women diagnosed with early breast cancer (EBC), before and after adjuvant chemotherapy.
DESIGN: 171 patients with early-stage breast adenocarcinomas were retrospectively evaluated. Immunoradiometric (IRMA) assays were employed for the in-vitro determination of IGF-1 and IGFBP-3 serum levels in blood samples collected after surgical treatment and before initiation of adjuvant chemotherapy. CTCs' presence was assessed through detection of cytokeratin-19 (CK-19) mRNA transcripts using quantitative real time reverse transcription polymerase chain reaction (RT-PCR). IGF-1, IGFBP-3 serum levels were correlated with CTCs' presence before and after adjuvant chemotherapy as well as with tumor characteristics including tumor size, axillary lymph node status, oestrogen (ER)/progestorene (PR) and human epidermural growth factor receptor 2 (HER2) receptor status. Log-rank test was applied to investigate possible association between IGF-1, IGFBP-3 serum levels and disease-free interval (DFI) and overall survival (OS).
RESULTS: Before initiation of adjuvant therapy IGF-1, IGFBP-3 serum levels were moderately associated (Spearman's rho=0.361, p<0.001) with each other, while presenting significant differences across age groups (all p values<0.05). IGF-1 serum levels did not correlate with the presence of CTCs before initiation (p=0.558) or after completion (p=0.474) of adjuvant chemotherapy. Similarly, IGFBP-3 serum levels did not show significant association with detectable CTCs either before (p=0.487) or after (p=0.134) completion of adjuvant chemotherapy. There was no statistically significant association between the clinical outcome of patients in terms of DFI, OS and IGF-1(DFI: p=0.499; OS: p=0.220) or IGFBP-3 (DFI: p=0.900; OS: p=0.406) serum levels.
CONCLUSIONS: IGF-1 and IGFBP-3 serum levels before initiation of adjuvant chemotherapy are not indicative of CTCs' presence in the blood and do not correlate with clinical outcome of women with early-stage breast cancer.
|
Language |
Greek |
Subject |
Biomarkers |
|
IGF-binding protein-3 |
|
Βιοδείκτες |
|
Κυκλοφορούντα καρκινικά κύτταρα |
Issue date |
2017-07-26 |
Collection
|
School/Department--School of Medicine--Department of Medicine--Doctoral theses
|
|
Type of Work--Doctoral theses
|
Permanent Link |
https://elocus.lib.uoc.gr//dlib/7/a/c/metadata-dlib-1505459746-431383-10948.tkl
|
Views |
485 |